Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435600 · ClinicalTrials.gov registry record · Phase 3
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
A Phase 3 study of Psoriasis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
- 20
- Study locations
NCT04435600 is a Phase 3 study of Psoriasis that has completed, run by AbbVie. The registered enrollment target is 139 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04435600, a Phase 3 study of Psoriasis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
- 20
- Study locations
Study Summary
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms. Risankizumab is a drug being studied for the treatment for plaque psoriasis in pediatric participants. This study has 4 parts. Part 1: Participants aged 12 \< 18 will receive a fixed dose of risankizumab. Part 2: Participants aged 12 \< 18 will receive; * Period A: Risankizumab or ustekinumab based on body weight followed by; * Period B: Risankizumab or no treatment. * Period C: Re-treatment with risankizumab (if needed). Part 3: Participants aged 6 \< 12 will receive risankizumab based on body weight. Part 4: Participants aged 6 \< 12 will receive risankizumab based on body weight (Japan only: Participants aged 12 \> 18 will receive risankizumab based on body weight). Around 132 participants will be enrolled in approximately 50 sites worldwide. Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection. Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks. Part 2: * Period A: Risankizumab or ustekinumab for 16 weeks. * Period B: Risankizumab or no treatment for 36 weeks. * Period C: Re-treatment with risankizumab for 16 weeks. Follow-up call 20 weeks later for a study duration of approximately 81 weeks. Participants from each Part who meet eligibility criteria for an open-label extension (OLE) study may continue on risankizumab for 216 additional weeks. There may be a higher burden for study participants compared to standard treatment. Participants will attend monthly visits and medical assessments will check the effect of treatment through blood tests, questionnai
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Risankizumab
Study Locations (20)
Florida
- Rybear, Inc /ID# 223164 - Fort Lauderdale
- Solutions Through Adv Rch /ID# 217936 - Jacksonville
- Olympian Clinical Research- St. Petersburg /ID# 217941 - St. Petersburg
- Advanced Clinical Research Institute /ID# 222706 - Tampa
California
- First OC Dermatology /ID# 217733 - Fountain Valley
- Integrative Skin Science and Research /ID# 221741 - Sacramento
- University of California San Diego - Rady Children's Hospital San Diego /ID# 217906 - San Diego
Ohio
- Univ Hosp Cleveland /ID# 228483 - Cleveland
- The Ohio State University /ID# 217808 - Columbus
- Apex Clinical Research Center /ID# 228537 - Mayfield Heights
Illinois
- University Dermatology and Vein Clinic, LLC /ID# 222778 - Darien
- Duplicate_Arlington Dermatology /ID# 217472 - Rolling Meadows
Alabama
- UAB Department of Dermatology /ID# 218834 - Birmingham
Nevada
- Duplicate_Skin Cancer and Dermatology Institute (SCDI) /ID# 221738 - Reno
New York
- Duplicate_Forest Hills Dermatology Group /ID# 227941 - Kew Gardens
Oklahoma
- Vital Prospects Clinical Research Institute, PC /ID# 217960 - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435600
The ClinicalTrials.gov registry entry for NCT04435600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (72% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT04435600 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT04435600 about?
NCT04435600 is a clinical study titled "A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms". Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants...
What is the current status of trial NCT04435600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2020-07-14. Estimated completion is 2024-10-15.
What conditions does trial NCT04435600 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04435600?
The interventions under investigation include: Ustekinumab (DRUG), Risankizumab (DRUG).
Who is sponsoring clinical trial NCT04435600?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04435600 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.